Summary & Overview
CPT 0489U: Unity Fetal Risk Screen, Cell‑free DNA Prenatal Genetic Screening
CPT code 0489U designates the Unity Fetal Risk Screen™, a proprietary prenatal test from BillionToOne Laboratory that uses cell-free DNA sequencing to identify paternally inherited pathogenic variants and assess fetal inheritance of maternal mutations for disorders such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies. As a PLA code, 0489U is unique to a single manufacturer's assay and is used when that specific test is performed. Nationally, PLA codes like 0489U are increasingly important as genomic diagnostics expand and payers evaluate coverage and coding policies for proprietary tests.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical purpose of the test, the typical service and site of service, and which major payers are considered. The publication summarizes reimbursement and coverage considerations for a proprietary fetal risk screen, highlights benchmarks and payer policy themes relevant to PLA codes, and situates the test within prenatal genetic screening practices. The content provides clinical context for ordering clinicians and billing professionals and outlines what to expect in payer engagement and coding use for this specific assay. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0489U is a Proprietary Laboratory Analyses (PLA) code that applies only to the Unity Fetal Risk Screen™ manufactured and performed by BillionToOne Laboratory, BillionToOne Inc. The test uses cell–free DNA sequencing to detect paternally inherited pathogenic variants and to determine whether the fetus has inherited a maternal mutation, producing a fetal risk score for conditions including cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies, and alpha thalassemia.
Service type: Noninvasive prenatal genetic screening using cell-free DNA sequencing
Typical site of service: Clinical laboratory or outpatient specimen collection site (blood draw) with results reported to ordering clinician
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant patient at 10–22 weeks gestation presents for prenatal genetic screening. The obstetrician or genetic counselor reviews family history revealing that one parent is a known carrier of a pathogenic variant for cystic fibrosis (CF), spinal muscular atrophy (SMA), beta hemoglobinopathies (including sickle cell disease and beta-thalassemia), or alpha thalassemia. The clinician orders the Unity Fetal Risk Screen™ (0489U) from BillionToOne Laboratory to assess fetal risk using cell-free DNA sequencing. A peripheral maternal blood draw is performed in the outpatient clinic or prenatal laboratory (typical site of service: outpatient laboratory or physician office). The sample is sent to the manufacturer’s laboratory for proprietary analysis. Results report a fetal risk score indicating whether the fetus likely inherited the maternal mutation and whether paternally inherited pathogenic variants are present. Results are reviewed by the ordering clinician; follow-up may include targeted diagnostic testing (amniocentesis or chorionic villus sampling) if a high-risk result is reported. Common payors reviewing claims include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified - standard procedure | When the test is billed without any modifier adjustments. |
| 26 | Professional component | When a separate physician professional component (interpretation) is billed in addition to the technical laboratory component.
| 52 | Reduced services | When the laboratory performs a reduced or partially completed test due to limited sample or other constraints.
| 53 | Discontinued procedure | If the test or specimen processing was discontinued prior to completion for documented clinical reasons.
| TC | Technical component | When billing only the laboratory technical component (specimen processing and analysis) without professional interpretation.
| 22 | Increased procedural services | If unusually complex laboratory work is required beyond the typical algorithm and documentation supports increased work.
| 90 | Reference (outside) laboratory | When the performing laboratory is an outside reference lab and payer requires a modifier indicating reference lab services.
| 91 | Repeat clinical diagnostic laboratory test | When an identical test is repeated on the same day to confirm analytic validity.
| 59 | Distinct procedural service | If a distinct and separate laboratory procedure is performed the same day that is not bundled with 0489U.
| GA | Waiver of liability statement on file (personal) | When patient has signed ABN-like documentation and payer requires notification that the patient accepted financial responsibility.
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Maternal and Fetal Medicine | Specialists who frequently order prenatal cell-free DNA tests and interpret risk results. |
| 207L00000X | Obstetrics & Gynecology | Primary obstetric providers ordering prenatal screening in outpatient settings.
| 2080P0202X | Clinical Genetics | Geneticists and genetic counselors who may order and interpret targeted fetal risk sequencing panels.
| 261QM0800X | Molecular Pathology | Laboratory directors and molecular pathologists overseeing sequencing-based assays.
| 2084P0800X | Pathology | Pathologists involved in oversight, interpretation, and reporting of laboratory genetic tests.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
O09.892 | Other pre-existing maternal hypertension complicating pregnancy, second trimester | Example maternal condition encountered in prenatal care; coexisting diagnoses commonly appear on prenatal panels when ordering fetal risk screening. |
| Z36.89 | Encounter for antenatal screening of other conditions | Directly relevant as a general screening encounter code used when ordering specialized prenatal genetic screening such as 0489U.
| Z35.0 | Supervision of pregnancy with history of infertility | High-risk prenatal supervision codes commonly accompany advanced genetic screening decisions.
| Z13.79 | Encounter for screening for other genetic and chromosomal anomalies | Used to denote genetic screening encounters including cell-free DNA paternally inherited variant screening.
| Z31.5 | Genetic counseling | When genetic counseling is provided in conjunction with ordering or reviewing results for 0489U.
| R10.9 | Abdominal pain, unspecified | Example symptom entry that may be present in the prenatal record; included commonly in visit documentation alongside screening orders.
| Z34.90 | Encounter for supervision of normal pregnancy, unspecified, third trimester | Routine prenatal supervision codes that may be associated with ordering screening earlier in pregnancy.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81025 | Urinalysis, automated, with microscopy | Performed as part of routine prenatal labs during the same visit where blood for 0489U is collected. |
| 36415 | Collection of venous blood by venipuncture | Standard blood draw code used when obtaining the maternal specimen for the 0489U test.
| 81420 | Molecular pathology procedure, Tier 2 (e.g., targeted genomic sequence analysis) | May be used for other non-proprietary prenatal molecular tests; complements or is used when alternative sequencing assays are performed instead of proprietary PLA codes.
| 88271 | FISH, prenatal, probe combination, each probe set (list separately in report) | Relevant when invasive diagnostic testing (amniocentesis) is performed following a high-risk 0489U result and cytogenetic testing is ordered.
| 76945 | Therapeutic, diagnostic ultrasound guidance for needle placement | Used when invasive diagnostic sampling (amniocentesis or CVS) is performed after abnormal prenatal screening results from 0489U.